Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
about
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@en
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@nl
type
label
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@en
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@nl
prefLabel
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@en
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@nl
P2093
P2860
P1476
Safety and pharmacokinetics of ...... phase I dose-escalation study.
@en
P2093
A Craig Lockhart
Alain C Mita
Chung-Tsen Hsueh
Claudine Wack
David I Quinn
James L Wade
James Mier
Jimmy Hwang
P2860
P2888
P304
P356
10.1007/S00280-016-3210-8
P50
P577
2017-01-05T00:00:00Z